Ascentage Pharma Group International
HKEX:6855.HK
44.1 (HKD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2024 Q2 | 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | 2018 Q4 | 2018 Q2 | 2018 Q1 | 2017 Q4 | 2017 Q2 | 2017 Q1 | 2016 Q4 | 2016 Q2 | 2016 Q1 | 2015 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 823.746 | 79.283 | 142.701 | 113.948 | 95.763 | 14.945 | 12.965 | 9.837 | 2.613 | 12.196 | 2.317 | 5.109 | 1.698 | 1.702 | 1.702 | 1.582 | 1.582 | 1.582 | 1.917 | 1.917 | 1.917 |
| Cost of Revenue
| 15.059 | 12.389 | 18.154 | 16.977 | 5.021 | 0.739 | 2.589 | 1.966 | 0 | 2.096 | 0 | 0.524 | 0 | 0 | 0 | 0 | 0 | 0 | 0.065 | 0.065 | 0.065 |
| Gross Profit
| 808.687 | 66.894 | 124.547 | 96.971 | 90.742 | 14.206 | 10.376 | 7.871 | 2.613 | 10.1 | 2.317 | 4.585 | 1.698 | 1.702 | 1.702 | 1.582 | 1.582 | 1.582 | 1.852 | 1.852 | 1.852 |
| Gross Profit Ratio
| 0.982 | 0.844 | 0.873 | 0.851 | 0.948 | 0.951 | 0.8 | 0.8 | 1 | 0.828 | 1 | 0.897 | 1 | 1 | 1 | 1 | 1 | 1 | 0.966 | 0.966 | 0.966 |
| Reseach & Development Expenses
| 444.079 | 397.158 | 309.814 | 401.695 | 341.409 | 448.948 | 317.543 | 313.116 | 251.455 | 264.901 | 198.982 | 173.111 | 76.454 | 62.391 | 62.391 | 29.704 | 29.704 | 29.704 | 25.673 | 25.673 | 25.673 |
| General & Administrative Expenses
| 86.988 | 89.555 | 91.34 | 88.122 | 82.349 | 79.335 | 63.927 | 66.968 | 61.699 | 99.577 | 61.79 | 42.038 | 47.183 | 15.375 | 15.375 | 3.351 | 3.351 | 3.351 | 4.427 | 4.427 | 4.427 |
| Selling & Marketing Expenses
| 89.637 | 112.068 | 83.319 | 86.085 | 71.336 | 37.155 | 10.593 | 1.372 | 0 | 0.276 | 0 | -7.606 | 4.897 | 4.897 | 4.897 | 1.194 | 1.194 | 1.194 | 0.407 | 0.407 | 0.407 |
| SG&A
| 176.625 | 201.804 | 174.659 | 174.331 | 153.685 | 116.741 | 74.52 | 68.643 | 61.699 | 99.853 | 61.79 | 42.534 | 47.183 | 20.272 | 20.272 | 4.545 | 4.545 | 4.545 | 4.834 | 4.834 | 4.834 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 620.704 | 598.962 | 477.462 | 552.865 | 478.962 | 467.572 | 379.634 | 360.621 | 324.274 | 859.651 | 643.714 | 236.364 | 87.493 | 82.663 | 82.663 | 34.249 | 34.249 | 34.249 | 30.507 | 30.507 | 30.507 |
| Operating Income
| 187.983 | -532.068 | -359.926 | -479.055 | -404.352 | -551.483 | -381.687 | -373.888 | -310.541 | -354.654 | -258.455 | -210.536 | -121.939 | -77.498 | -77.498 | -15.545 | -15.545 | -15.545 | -26.145 | -26.145 | -26.145 |
| Operating Income Ratio
| 0.228 | -6.711 | -2.522 | -4.204 | -4.222 | -36.901 | -29.44 | -38.008 | -118.845 | -29.08 | -111.547 | -41.209 | -71.813 | -45.54 | -45.54 | -9.826 | -9.826 | -9.826 | -13.64 | -13.64 | -13.64 |
| Total Other Income Expenses Net
| -25.088 | -1.191 | -39.677 | -5.865 | 2.1 | 93.61 | 7.311 | 18.418 | -9.437 | -493.546 | -375.661 | -18.689 | 4.255 | -9.23 | -9.23 | -14.485 | -14.485 | -14.485 | -0.815 | -0.815 | -0.815 |
| Income Before Tax
| 162.895 | -533.259 | -399.603 | -484.92 | -402.252 | -457.873 | -374.376 | -355.47 | -319.978 | -848.2 | -634.116 | -229.225 | -117.684 | -86.727 | -86.727 | -30.029 | -30.029 | -30.029 | -26.96 | -26.96 | -26.96 |
| Income Before Tax Ratio
| 0.198 | -6.726 | -2.8 | -4.256 | -4.2 | -30.637 | -28.876 | -36.136 | -122.456 | -69.547 | -273.68 | -44.867 | -69.307 | -50.964 | -50.964 | -18.982 | -18.982 | -18.982 | -14.065 | -14.065 | -14.065 |
| Income Tax Expense
| 0.069 | 9.896 | 2.746 | 8.73 | 4.482 | 52.131 | 2.306 | 2.959 | 0.801 | 0.801 | 0.801 | 0.801 | 0.801 | -0.401 | -0.401 | -0.401 | -0.401 | -0.401 | 0.815 | 0.815 | 0.815 |
| Net Income
| 163.001 | -523.286 | -402.351 | -476.19 | -406.734 | -405.742 | -376.682 | -358.429 | -319.177 | -847.399 | -633.315 | -228.424 | -116.883 | -86.327 | -86.327 | -29.629 | -29.629 | -29.629 | -27.775 | -27.775 | -27.775 |
| Net Income Ratio
| 0.198 | -6.6 | -2.82 | -4.179 | -4.247 | -27.149 | -29.054 | -36.437 | -122.15 | -69.482 | -273.334 | -44.71 | -68.836 | -50.728 | -50.728 | -18.729 | -18.729 | -18.729 | -14.49 | -14.49 | -14.49 |
| EPS
| 0.55 | -1.8 | -1.47 | -1.81 | -1.54 | -1.55 | -1.52 | -1.61 | -1.53 | -6.22 | -6.51 | -1.96 | -0.56 | -0.42 | -0.42 | -0.14 | -0.14 | -0.14 | -0.13 | -0.13 | -0.13 |
| EPS Diluted
| 0.55 | -1.8 | -1.47 | -1.81 | -1.54 | -1.55 | -1.52 | -1.61 | -1.53 | -6.22 | -6.51 | -1.96 | -0.56 | -0.42 | -0.42 | -0.14 | -0.14 | -0.14 | -0.13 | -0.13 | -0.13 |
| EBITDA
| 229.586 | -492.673 | -320.147 | -454.918 | -381.068 | -543.245 | -372.742 | -365.986 | -301.478 | -346.043 | -250.216 | -203.173 | -115.253 | -72.882 | -72.882 | -12.419 | -12.419 | -12.419 | -25.758 | -25.758 | -25.758 |
| EBITDA Ratio
| 0.279 | -6.214 | -2.243 | -3.992 | -3.979 | -36.35 | -28.75 | -37.205 | -115.376 | -28.373 | -107.991 | -39.768 | -67.876 | -42.828 | -42.828 | -7.85 | -7.85 | -7.85 | -13.439 | -13.439 | -13.439 |